Table 2 Clinical characteristics of individuals with substance use disorders group
From: Assessing emotional intelligence domains and levels in substance use disorders
Variables | Individuals with substance use disorders (n = 50) | |
|---|---|---|
No. | % | |
Diagnosis | Â | Â |
 Single substance | 27 | 54.0 |
 Poly substance | 23 | 46.0 |
Types of substance usea | Â | Â |
 Cannabinoids | 17 | 34.0 |
 Opioids | 30 | 60.0 |
 Tramadol | 15 | 30.0 |
 Amphetamines | 15 | 30.0 |
 Benzodiazepine | 2 | 4.0 |
Methods of substance usea | Â | Â |
 Oral | 24 | 48.0 |
 Inhalation | 38 | 76.0 |
 Injection | 7 | 14.0 |
Age of at onset abuse (in years): (mean ± SD) | 21.82 ± 5.98 | |
 < 20 | 20 | 40.0 |
 20–30 | 26 | 52.0 |
 > 30 | 4 | 8.0 |
Duration of abuse (days) | Â | Â |
(mean ± SD) Median (interquartile range) | 7855.20 ± 2151.03 7740 (2880) | |
Motivation for initiating substancea | ||
 Peer effect | 38 | 76.0 |
 Trial | 19 | 38.0 |
 Increase strength and energy | 4 | 8.0 |
 Escape from life stressors | 10 | 20.0 |
 Relieve chronic pain | 1 | 2.0 |